Literature DB >> 24919440

Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells.

Kai Chen1, Chunyan Zhu, Ming Cai, Dong Fu, Biao Cheng, Zhengdong Cai, Guodong Li, Jilong Liu.   

Abstract

BACKGROUND: Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. However, few biomarkers of diagnostic significance have been established. In recent years, high-throughput transcriptomic and metabolomic approaches make it possible for studying the levels of thousands of biomarkers simultaneously.
METHODS: In this study, we integrated two disparate transcriptomic and metabolomic datasets to find meaningful biomarkers and then used an independent dataset to test the sensibility and specificity of these biomarkers.
RESULTS: By using integrated two datasets, we discovered that the biomarkers involved in the glycolysis pathway are highly enriched, including 4 genes (ENO1, TPI1, PKG1 and LDHC) and 2 metabolites (lactate and pyruvate). The 4 genes were significantly down-regulated in OS samples as well as the 2 metabolites. The mixed metabolites + genes signature also outperformed metabolites or genes alone, with recall being 0.813 and F-measure being 0.812. And the AUC value of metabolites + genes classifier was 0.825 (compared to 0.58 for metabolites and 0.821 for genes alone).
CONCLUSION: Our findings establish that integrated transcriptomic and metabolomic signature can be used to distinguish OS malignant with good diagnostic accuracy superior to other methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919440     DOI: 10.1007/s00432-014-1719-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  Support vector machine classification and validation of cancer tissue samples using microarray expression data.

Authors:  T S Furey; N Cristianini; N Duffy; D W Bednarski; M Schummer; D Haussler
Journal:  Bioinformatics       Date:  2000-10       Impact factor: 6.937

Review 2.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma.

Authors:  Avery Sandberg; Julia Bridge
Journal:  Cancer Genet Cytogenet       Date:  2002-07-01

3.  Meta-analysis for pathway enrichment analysis when combining multiple genomic studies.

Authors:  Kui Shen; George C Tseng
Journal:  Bioinformatics       Date:  2010-04-21       Impact factor: 6.937

4.  Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma.

Authors:  J Toguchida; K Ishizaki; M S Sasaki; Y Nakamura; M Ikenaga; M Kato; M Sugimot; Y Kotoura; T Yamamuro
Journal:  Nature       Date:  1989-03-09       Impact factor: 49.962

5.  Increased expression of serum gelsolin in patients with osteosarcoma.

Authors:  Song Jin; Jing-Nan Shen; Jian-Qiang Peng; Jin Wang; Gang Huang; Ming-Tao Li
Journal:  Chin Med J (Engl)       Date:  2012-01       Impact factor: 2.628

6.  Serum and urinary metabonomic study of human osteosarcoma.

Authors:  Zhiyu Zhang; Yunping Qiu; Yingqi Hua; Yihuang Wang; Tianlu Chen; Aihua Zhao; Yi Chi; Li Pan; Shuo Hu; Jian Li; Chengwei Yang; Guodong Li; Wei Sun; Zhengdong Cai; Wei Jia
Journal:  J Proteome Res       Date:  2010-09-03       Impact factor: 4.466

7.  Osteogenic sarcoma (osteosarcoma): results of therapy.

Authors:  J J Stein
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-03

8.  Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma.

Authors:  José Antonio López-Guerrero; Concha López-Ginés; Antonio Pellín; Carmen Carda; Antonio Llombart-Bosch
Journal:  Diagn Mol Pathol       Date:  2004-06

9.  An integrative multi-platform analysis for discovering biomarkers of osteosarcoma.

Authors:  Guodong Li; Wenjuan Zhang; Huazong Zeng; Lei Chen; Wenjing Wang; Jilong Liu; Zhiyu Zhang; Zhengdong Cai
Journal:  BMC Cancer       Date:  2009-05-16       Impact factor: 4.430

  9 in total
  10 in total

Review 1.  Application of metabolomics in sarcoma: From biomarkers to therapeutic targets.

Authors:  Li Min; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Crit Rev Oncol Hematol       Date:  2017-05-13       Impact factor: 6.312

2.  Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.

Authors:  Lin-Lin Cao; Zhaoming Chen; Zhihong Yue; Lin Pei; Mei Jia; Hui Wang; Tingting Li
Journal:  J Clin Lab Anal       Date:  2020-01-08       Impact factor: 2.352

3.  Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.

Authors:  Yong An; Huihua Cai; Yong Yang; Yue Zhang; Shengyong Liu; Xinquan Wu; Yunfei Duan; Donglin Sun; Xuemin Chen
Journal:  Cancer Sci       Date:  2018-09-03       Impact factor: 6.716

4.  Evaluating a Panel of Autoantibodies Against Tumor-Associated Antigens in Human Osteosarcoma.

Authors:  Manli Luo; Songmei Wu; Yan Ma; Hong Liang; Yage Luo; Wentao Gu; Lijuan Fan; Yang Hao; Haiting Li; Linbo Xing
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

5.  Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.

Authors:  Tingting Fan; Zhuona Rong; Jianyi Dong; Juan Li; Kangwei Wang; Xinxin Wang; Huiling Li; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

6.  Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.

Authors:  Sha Lou; Benjamin Balluff; Arjen H G Cleven; Judith V M G Bovée; Liam A McDonnell
Journal:  J Am Soc Mass Spectrom       Date:  2016-11-21       Impact factor: 3.109

Review 7.  Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets.

Authors:  Zijian Zou; Wei Sun; Yu Xu; Wanlin Liu; Jingqin Zhong; Xinyi Lin; Yong Chen
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

8.  Targeting Nuclear NAD+ Synthesis Inhibits DNA Repair, Impairs Metabolic Adaptation and Increases Chemosensitivity of U-2OS Osteosarcoma Cells.

Authors:  Alexandra Kiss; Arnold Péter Ráduly; Zsolt Regdon; Zsuzsanna Polgár; Szabolcs Tarapcsák; Isotta Sturniolo; Tarek El-Hamoly; László Virág; Csaba Hegedűs
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

9.  Insights in Osteosarcoma by Proton Nuclear Magnetic Resonance Serum Metabonomics.

Authors:  Melissa Quintero Escobar; Tássia Brena Barroso Carneiro Costa; Lucas G Martins; Silvia S Costa; André vanHelvoort Lengert; Érica Boldrini; Sandra Regina Morini da Silva; Luiz Fernando Lopes; Daniel Onofre Vidal; Ana C V Krepischi; Mariana Maschietto; Ljubica Tasic
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

Review 10.  Metabolomics in Bone Research.

Authors:  Jingzhi Fan; Vahid Jahed; Kristaps Klavins
Journal:  Metabolites       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.